Medtronic (NYSE:MDT) said today it won Health Canada approval for its OsteoCool radiofrequency ablation system for treating cancers that metastasize to the spine, and launched the system in the region.
The Fridley, Minn.-based company touted the OsteoCool system as the only cooled RF ablation technology with simultaneous, dual-probe capabilities.
“Our pain therapies business is deeply rooted in the Medtronic mission – which calls us to alleviate pain. We put an important treatment option into the hands of physicians so they can help more patients suffering from debilitating cancer pain,” Medtronic Canada restorative therapy group senior director Sandrine Moirez said in a prepared statement.
The OsteoCool system is temperature controlled and uses internally water-cooled probes to prevent overheating and damage to surrounding tissue during the procedure, Medtronic said. The systems’ 17-gauge, bipolar probes are available in 3 lengths and are usable at a variety of cannula sizes.
“Osteocool radiofrequency ablation provides a minimally invasive option for the treatment of painful bone metastases and is particularly useful in patients that have not responded well to other treatment modalities,” Dr. Roy Park of Calgary’s EFW Radiology said in a press release.
In February, Medtronic won an expanded indication from the FDA for its OsteoCool RF ablation device for palliative treatment of metastases in all bony anatomy.
Medtronic acquired the technology when it bought Baylis Medical for an undisclosed amount back in December 2015. The original OsteoCool device 1st won 510(k) clearance in March 2012. A 2nd version landed another 510(k) in June 2015, and Montreal-based Baylis won a nod in November 2015 for the 3rd iteration.